FDA Rejects Gilead’s Hepatitis D Therapy Hepcludex

The FDA has declined to green-light Gilead Sciences’ hepatitis delta virus (HDV) drug bulevirtide because of manufacturing and delivery concerns, meaning there will continue to be no approved treatment for the condition in the U.S.
Source: Drug Industry Daily